A pooled analysis evaluating data from 3 clinical trials (CheckMate-057, KEYNOTE-010 and POPLAR) confirmed that PD-1/PD-L1 ICIs did not enhance OS versus docetaxel in advanced NSCLC patients bearing EGFR mutation (n = 186, HR = 1.05, 95% CI: 0.70-1.55, P < 0.81) (47). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.